Aprepitant and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Aprepitant
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Aprepitant (used to prevent nausea, brands like Emend or Cinvanti) can slow down the body enzyme that breaks down cariprazine (Vraylar). When that enzyme is slowed, more cariprazine and its active leftover product can build up in your system. That can mean stronger effects and a higher chance of side effects like restlessness, drowsiness, or muscle stiffness.
The good news is this is very manageable. Your care team knows how to handle it, usually by adjusting your cariprazine dose and keeping a closer eye on how you feel. Please keep taking both medicines as prescribed, and check with your pharmacist or doctor so they can tailor your dose.
Mechanism: Cariprazine and its active metabolite (didesmethylcariprazine, DDCAR) are CYP3A4 substrates. Aprepitant is a moderate CYP3A4 inhibitor, so coadministration is expected to increase cariprazine/DDCAR exposure (increased drug effect). Evidence is theoretical; severity rated major.
Management (per labeling for a moderate CYP3A4 inhibitor):
- Initiating cariprazine on inhibitor (schizophrenia/bipolar mania): start 1.5 mg every other day, titrate per response/tolerability.
- Bipolar depression or adjunctive MDD: 1.5 mg every other day.
- Stable 1.5 or 3 mg/day then adding inhibitor: reduce to 1.5 mg every other day.
- Stable 4.5 or 6 mg/day: reduce to 1.5 mg once daily.
- On inhibitor discontinuation, dose may need to be increased per response.
Monitor for extrapyramidal symptoms, akathisia, and sedation. Note aprepitant's inhibition is also time-limited.
What happens
Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure
Interaction Deep Dive
Giving cariprazine (a CYP3A4 substrate) together with a moderate CYP3A4 inhibitor can raise the exposure of both cariprazine itself and its active metabolite, didesmethylcariprazine. If cariprazine is being started in a patient already receiving a moderate CYP3A4 inhibitor for schizophrenia or bipolar mania, the initial dose should be 1.5 mg orally every other day, with a subsequent increase to 1.5 mg orally every other day if warranted by clinical response and tolerability. For patients on a moderate CYP3A4 inhibitor being treated for bipolar depression or as adjunctive therapy for major depressive disorder (MDD), the dose is 1.5 mg orally every other day. When a moderate CYP3A4 inhibitor is added to a patient already stabilized on cariprazine, dose adjustments apply as follows: for those taking 1.5 or 3 mg once daily, change cariprazine to 1.5 mg orally every other day upon starting the inhibitor; for those taking 4.5 or 6 mg once daily, change cariprazine to 1.5 mg orally once daily upon starting the inhibitor. If the moderate CYP3A4 inhibitor is later stopped, the cariprazine dose may require an increase guided by clinical response and tolerability. In addition, using cariprazine (a CYP3A4 substrate) alongside a CYP3A4 inducer is not advised. The formation and clearance of cariprazine's active metabolites depend on CYP3A4. Since the impact of CYP3A4 inducers on cariprazine exposure has not been studied, the overall effect remains uncertain1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine; induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This interaction is well characterized enough that your care team has clear ways to manage it. Keep taking both medicines exactly as prescribed unless told otherwise.
- Your cariprazine dose may be adjusted (often lowered or spaced further apart) while you are also taking aprepitant.
- If aprepitant is later stopped, your cariprazine dose may need to be increased again based on how you respond.
- Your team may monitor you more closely for side effects such as restlessness, muscle stiffness, tremor, or drowsiness.
Tell your pharmacist or prescriber that you take both, and report any new or worsening symptoms so your dose can be individualized.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 1.5 mg/day together with erythromycin (a moderate CYP3A4 inhibitor) 500 mg twice daily over 21 days led to an increase in cariprazine AUC (0 to 24 hours) and Cmax of about 50% 1.
Common questions
Can I take Aprepitant and Cariprazine together?
Aprepitant can raise cariprazine levels and side-effect risk, so your doctor may lower or space out your cariprazine dose while you take both. Keep taking both as prescribed and report any new symptoms. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Aprepitant and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Aprepitant and Cariprazine interaction managed?
This interaction is well characterized enough that your care team has clear ways to manage it. Keep taking both medicines exactly as prescribed unless told otherwise. Your cariprazine dose may be adjusted (often lowered or spaced further apart) while you are also taking aprepitant. If aprepitant is later stopped, your cariprazine dose may need to be increased again based on how you respond. Your t… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Aprepitant or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Aprepitant
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist